Jeremy Bender Sells 13,964 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 13,964 shares of the business’s stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $87,414.64. Following the transaction, the chief executive officer now owns 145,737 shares in the company, valued at $912,313.62. The trade was a 8.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jeremy Bender also recently made the following trade(s):

• On Tuesday, February 18th, Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock opened at $6.48 on Tuesday. The company has a market capitalization of $656.83 million, a price-to-earnings ratio of -6.29 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a 52-week low of $6.08 and a 52-week high of $16.76. The company has a 50-day simple moving average of $7.40 and a two-hundred day simple moving average of $10.71.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. The business had revenue of $30.76 million for the quarter, compared to analysts’ expectations of $30.28 million. On average, sell-side analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in DAWN. SG Americas Securities LLC purchased a new position in Day One Biopharmaceuticals in the fourth quarter valued at about $866,000. MetLife Investment Management LLC increased its position in Day One Biopharmaceuticals by 12.4% in the fourth quarter. MetLife Investment Management LLC now owns 34,248 shares of the company’s stock worth $434,000 after buying an additional 3,781 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of Day One Biopharmaceuticals by 90.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company’s stock valued at $1,535,000 after buying an additional 57,601 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Day One Biopharmaceuticals by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 535,501 shares of the company’s stock worth $6,785,000 after acquiring an additional 28,053 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Day One Biopharmaceuticals by 43.4% in the 4th quarter. Bank of New York Mellon Corp now owns 244,829 shares of the company’s stock worth $3,102,000 after acquiring an additional 74,091 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on DAWN shares. The Goldman Sachs Group dropped their price target on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday, March 25th. Wedbush reiterated an “outperform” rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Needham & Company LLC lowered their price objective on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $30.57.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.